Innate Pharma S.A.

ENXTPA:IPH 株式レポート

時価総額:€162.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Innate Pharma 配当金

配当金 基準チェック /06

Innate Pharma配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り1.5%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
一株当たり利益-€0.42
配当利回り予想n/a

最近の配当金アップデート

更新なし

Recent updates

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Jun 09
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Mar 30
News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Dec 18
Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Sep 27
Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Aug 04
Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

May 12
Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Apr 13
Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Mar 26
Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Nov 11
Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Revenue Downgrade: Here's What Analysts Forecast For Innate Pharma S.A. (EPA:IPH)

May 13
Revenue Downgrade: Here's What Analysts Forecast For Innate Pharma S.A. (EPA:IPH)

Is Innate Pharma (EPA:IPH) Using Debt Sensibly?

May 04
Is Innate Pharma (EPA:IPH) Using Debt Sensibly?

決済の安定と成長

配当データの取得

安定した配当: IPHの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: IPHの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Innate Pharma 配当利回り対市場
IPH 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (IPH)n/a
市場下位25% (FR)1.9%
市場トップ25% (FR)5.5%
業界平均 (Biotechs)1.5%
アナリスト予想 (IPH) (最長3年)n/a

注目すべき配当: IPHは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: IPHは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: IPHの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: IPHが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘